BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, development of drug candidates for health solutions.BELLUS Health Inc is a Canada based biopharmaceutical development company engaged in advancing novel therapeutics. It is involved in developing drugs for health solutions.